US 12,295,968 B2
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
Atul Bedi, Timonium, MD (US); and Rajani Ravi, Ruxton, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Sep. 12, 2024, as Appl. No. 18/883,719.
Application 15/362,632 is a division of application No. 15/231,309, filed on Aug. 8, 2016, granted, now 9,850,306, issued on Dec. 26, 2017.
Application 18/883,719 is a continuation of application No. 17/694,541, filed on Mar. 14, 2022.
Application 17/694,541 is a continuation of application No. 16/601,347, filed on Oct. 14, 2019, granted, now 11,274,156, issued on Mar. 15, 2022.
Application 16/601,347 is a continuation of application No. 15/362,632, filed on Nov. 28, 2016, granted, now 10,442,860, issued on Oct. 15, 2019.
Application 15/231,309 is a continuation of application No. 14/645,282, filed on Mar. 11, 2015, granted, now 9,441,044, issued on Sep. 13, 2016.
Application 14/645,282 is a continuation of application No. 13/582,717, granted, now 8,993,524, issued on Mar. 31, 2015, previously published as PCT/US2011/027317, filed on Mar. 4, 2011.
Claims priority of provisional application 61/435,671, filed on Jan. 24, 2011.
Claims priority of provisional application 61/311,255, filed on Mar. 5, 2010.
Prior Publication US 2025/0009772 A1, Jan. 9, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/71 (2006.01); A61K 31/704 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 14/495 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 19/00 (2006.01); A61K 38/18 (2006.01); A61K 39/00 (2006.01)
CPC A61K 31/704 (2013.01) [A61K 38/179 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); C07K 14/495 (2013.01); C07K 14/70532 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 14/71 (2013.01); C07K 16/28 (2013.01); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/2827 (2013.01); C07K 16/2851 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/30 (2013.01); C07K 19/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/33 (2013.01); C07K 2317/526 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/70 (2013.01)] 9 Claims
 
1. An isolated molecule comprising:
(a) a targeting moiety comprising an antibody or antibody fragment thereof, comprising amino acids 1-119 of SEQ ID NO: 2 and the amino acid sequence of SEQ ID NO: 71, which specifically binds Epidermal Growth Factor Receptor (EGFR); and
(b) an immunomodulatory moiety comprising an amino acid sequence of the extracellular domain of Transforming growth factor-beta receptor II (TGF-βRII) comprising the amino acid sequence of SEQ ID NO: 87.